EGFR Expression in Breast Cancer Association with biologic phenotype and clinical outcomes

Por Rimawi, Mothaffar F., Shetty, Priya B., Weiss, Heidi L., Schiff, Rachel, Osborne, C. Kent, Chamness, Gary C., Elledge, Richard M.
Publicado em 2010

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

Por Veeraraghavan, Jamunarani, De Angelis, Carmine, Reis-Filho, Jorge S., Prat, Aleix, Rimawi, Mothaffar F., Pascual, Tomás, Osborne, C. Kent, Schiff, Rachel
Publicado no Breast (2017)

THERAPEUTIC POTENTIAL OF THE DUAL EGFR/HER2 INHIBITOR AZD8931 IN CIRCUMVENTING ENDOCRINE RESISTANCE

Por Morrison, Gladys, Fu, Xiaoyong, Shea, Marty, Nanda, Sarmistha, Giuliano, Mario, Wang, Tao, Klinowska, Teresa, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Publicado em 2014

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

Por Huang, Catherine, Park, Catherine C, Hilsenbeck, Susan G, Ward, Robin, Rimawi, Mothaffar F, Wang, Yen-chao, Shou, Jiang, Bissell, Mina J, Osborne, C Kent, Schiff, Rachel
Publicado em 2011

Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER-2/neu Overexpressing Breast Tumor Xenografts

Por Rimawi, Mothaffar F., Wiechmann, Lisa S., Wang, Yen-Chao, Huang, Catherine, Migliaccio, Ilenia, Wu, Meng-Fen, Gutierrez, Carolina, Hilsenbeck, Susan G., Arpino, Grazia, Massarweh, Suleiman, Ward, Robin, Soliz, Robert, Osborne, C. Kent, Schiff, Rachel
Publicado em 2010

High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy

Por Litzenburger, Beate C., Creighton, Chad J., Tsimelzon, Anna, Chan, Bonita T., Hilsenbeck, Susan G., Wang, Tao, Carboni, Joan M., Gottardis, Marco M., Huang, Fei, Chang, Jenny C., Lewis, Michael T., Rimawi, Mothaffar F., Lee, Adrian V.
Publicado em 2010

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexp...

Por Rimawi, Mothaffar F., Mayer, Ingrid A., Forero, Andres, Nanda, Rita, Goetz, Matthew P., Rodriguez, Angel A., Pavlick, Anne C., Wang, Tao, Hilsenbeck, Susan G., Gutierrez, Carolina, Schiff, Rachel, Osborne, C. Kent, Chang, Jenny C.
Publicado em 2013

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation

Por Wang, Yen-Chao, Morrison, Gladys, Gillihan, Ryan, Guo, Jun, Ward, Robin M, Fu, Xiaoyong, Botero, Maria F, Healy, Nuala A, Hilsenbeck, Susan G, Phillips, Gail Lewis, Chamness, Gary C, Rimawi, Mothaffar F, Osborne, C Kent, Schiff, Rachel
Publicado em 2011

Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27

Por Niravath, Polly, Chen, Bingshu, Chapman, Judy-Anne W., Agarwal, Sandeep K., Welschhans, Robert L., Bongartz, Tim, Kalari, Krishna R., Shepherd, Lois E., Bartlett, John, Pritchard, Kathleen, Gelmon, Karen, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, Goss, Paul E., Ingle, James N.
Publicado no Clin Breast Cancer (2017)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

Por Nardone, Agostina, Weir, Hazel, Delpuech, Oona, Brown, Henry, De Angelis, Carmine, Cataldo, Maria Letizia, Fu, Xiaoyong, Shea, Martin J., Mitchell, Tamika, Veeraraghavan, Jamunarani, Nagi, Chandandeep, Pilling, Mark, Rimawi, Mothaffar F., Trivedi, Meghana, Hilsenbeck, Susan G., Chamness, Gary C., Jeselsohn, Rinath, Osborne, C. Kent, Schiff, Rachel
Publicado no Br J Cancer (2018)

Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes

Por Marusyk, Andriy, Tabassum, Doris P., Janiszewska, Michalina, Place, Andrew E., Trinh, Anne, Rozhok, Andrii I., Pyne, Saumyadipta, Guerriero, Jennifer L., Shu, Shaokun, Ekram, Muhammad, Ishkin, Alexander, Cahill, Daniel P., Nikolsky, Yuri, Chan, Timothy A., Rimawi, Mothaffar F., Hilsenbeck, Susan, Schiff, Rachel, Osborne, Kent C., Letai, Antony, Polyak, Kornelia
Publicado no Cancer Res (2016)

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predi...

Por Lin, Nancy U., Guo, Hao, Yap, Jeffrey T., Mayer, Ingrid A., Falkson, Carla I., Hobday, Timothy J., Dees, E. Claire, Richardson, Andrea L., Nanda, Rita, Rimawi, Mothaffar F., Ryabin, Nicole, Najita, Julie S., Barry, William T., Arteaga, Carlos L., Wolff, Antonio C., Krop, Ian E., Winer, Eric P., Van den Abbeele, Annick D.
Publicado no J Clin Oncol (2015)

Chemotherapy for Isolated Locoregional Recurrence of Breast Cancer: The CALOR Randomised Trial

Por Aebi, Stefan, Gelber, Shari, Anderson, Stewart J., Láng, István, Robidoux, André, Martín, Miguel, Nortier, Johan W.R., Paterson, Alexander H.G., Rimawi, Mothaffar F., Cañada, José Manuel Baena, Thürlimann, Beat, Murray, Elizabeth, Mamounas, Eleftherios P., Geyer, Charles E., Price, Karen N., Coates, Alan S., Gelber, Richard D., Rastogi, Priya, Wolmark, Norman, Wapnir, Irene L.
Publicado em 2014

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Por Carey, Lisa A., Rugo, Hope S., Marcom, P. Kelly, Mayer, Erica L., Esteva, Francisco J., Ma, Cynthia X., Liu, Minetta C., Storniolo, Anna Maria, Rimawi, Mothaffar F., Forero-Torres, Andres, Wolff, Antonio C., Hobday, Timothy J., Ivanova, Anastasia, Chiu, Wing-Keung, Ferraro, Madlyn, Burrows, Emily, Bernard, Philip S., Hoadley, Katherine A., Perou, Charles M., Winer, Eric P.
Publicado em 2012

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial

Por Wapnir, Irene L., Price, Karen N., Anderson, Stewart J., Robidoux, André, Martín, Miguel, Nortier, Johan W.R., Paterson, Alexander H.G., Rimawi, Mothaffar F., Láng, István, Baena-Cañada, José Manuel, Thürlimann, Beat, Mamounas, Eleftherios P., Geyer, Charles E., Gelber, Shari, Coates, Alan S., Gelber, Richard D., Rastogi, Priya, Regan, Meredith M., Wolmark, Norman, Aebi, Stefan
Publicado no J Clin Oncol (2018)

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis

Por Giuliano, Mario, Herrera, Sabrina, Christiny, Pavel, Shaw, Chad, Creighton, Chad J, Mitchell, Tamika, Bhat, Raksha, Zhang, Xiaomei, Mao, Sufeng, Dobrolecki, Lacey E, Al-rawi, Ahmed, Chen, Fengju, Veneziani, Bianca M, Zhang, Xiang H-F, Hilsenbeck, Susan G, Contreras, Alejandro, Gutierrez, Carolina, Jeselsohn, Rinath M, Rimawi, Mothaffar F, Osborne, C Kent, Lewis, Michael T, Schiff, Rachel, Trivedi, Meghana V
Publicado no Breast Cancer Res (2015)

Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy

Por Giuliano, Mario, Hu, Huizhong, Wang, Yen-Chao, Fu, Xiaoyong, Nardone, Agostina, Herrera, Sabrina, Mao, Sufeng, Contreras, Alejandro, Gutierrez, Carolina, Wang, Tao, Hilsenbeck, Susan G., De Angelis, Carmine, Wang, Nicholas J., Heiser, Laura M., Gray, Joe W., Lopez-Tarruella, Sara, Pavlick, Anne C., Trivedi, Meghana V., Chamness, Gary C., Chang, Jenny C., Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Publicado no Clin Cancer Res (2015)

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

Por Fu, Xiaoyong, Pereira, Resel, De Angelis, Carmine, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Cataldo, Maria L., Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Gutierrez, Carolina, Chamness, Gary C., Feng, Qin, O’Malley, Bert W., Selenica, Pier, Weigelt, Britta, Reis-Filho, Jorge S., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Brown, Myles, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel
Publicado no Proc Natl Acad Sci U S A (2019)

Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer

Por Sethunath, Vidyalakshmi, Hu, Huizhong, Angelis, Carmine De, Veeraraghavan, Jamunarani, Qin, Lanfang, Wang, Nicholas, Simon, Lukas M., Wang, Tao, Fu, Xiaoyong, Nardone, Agostina, Pereira, Resel, Nanda, Sarmistha, Griffith, Obi L., Tsimelzon, Anna, Shaw, Chad, Chamness, Gary C., Reis-Filho, Jorge S., Weigelt, Britta, Heiser, Laura M., Hilsenbeck, Susan G., Huang, Shixia, Rimawi, Mothaffar F., Gray, Joe W., Osborne, C. Kent, Schiff, Rachel
Publicado no Mol Cancer Res (2019)

Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy

Por De Angelis, Carmine, Nagi, Chandandeep, Hoyt, Cliff C., Liu, Linying, Roman, Kristin, Wang, Chichung, Zheng, Yi, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Nuciforo, Paolo, Wang, Tao, Tsimelzon, Anna, Mao, Sufeng, Hilsenbeck, Susan G., Trivedi, Meghana V., Cataldo, Maria Letizia, Pavlick, Anne C., Wolff, Antonio C., Weigelt, Britta, Reis-Filho, Jorge S., Prat, Aleix, Gutierrez, Carolina, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Publicado no Clin Cancer Res (2019)